Vascular Biogenics Ltd (VBLT)

[davidal66]

I sold my position Monday. I believed holding through the interim was too risky. Having said that, I do believe VB-111 "works" but rGBM may have been the wrong initial target... a literal and metaphorical graveyard for so many cancer targets. I do fear they won't past futility in the interim. I think there is a chance I'm wrong, but too risky at this juncture based on Dror'r cryptic comments on the last KOL about worrying about powering trials adequately, my own unscientific review of public posting regarding VB-111 on Inspire/Facebook/Blogs, and, most important, my review of how anti-angiogenics and immune based targets have performed(in the negative)in rGBM.

I'm still bullish on the VB600 series, NASH prospects, but it's early(and very interesting) and other potential indications for VB111.